Larotrectinib - Lucilaro
|
What it treats: |
Larotrectinib is considered a "tumor-agnostic" treatment, meaning it targets a specific genetic abnormality (NTRK gene fusion) rather than the tumor's location in the body. |
|
25 various cancers: Lung cancer, Colorectal cancer, Cancerous goiter, Secretory breast cancer, Infantile fibrosarcoma, stomach, pancrease, etc |
It is specifically used for tumors that harbor NTRK gene fusions, which can occur in a variety of solid tumors across different locations in the body. Advanced or Metastatic Cancer: It is used when the cancer has spread (metastatic) or when surgical removal is not an option or is likely to cause severe complications. No Satisfactory Alternative Treatments: Larotrectinib is typically considered when other treatment options have been exhausted or are not suitable. Pediatric Use: It is approved for use in children, including infants as young as 4 weeks old, with NTRK fusion-positive solid tumors. Efficacy: Clinical trials have shown that larotrectinib can be effective in shrinking tumors and achieving durable responses in patients with NTRK fusion-positive solid tumors. |